Tecovirimat Resistance in Mpox Patients, United States, 2022–2023

Tecovirimat Resistance in Mpox Patients, United States, 2022–2023

During the 2022 multinational outbreak of monkeypox virus (MPXV) infection, the antiviral drug tecovirimat (TPOXX; SIGA Technologies, Inc., https://www.siga.com) was deployed in the United States on a large scale for the first time. The MPXV F13L gene homologue encodes the target of tecovirimat, an...

Full description

Bibliographic Details
Main Authors: Todd G. Smith, Crystal M. Gigante, Nhien T. Wynn, Audrey Matheny, Whitni Davidson, Yong Yang, Rene Edgar Condori, Kyle O’Connell, Lynsey Kovar, Tracie L. Williams, Yon C. Yu, Brett W. Petersen, Nicolle Baird, David Lowe, Yu Li, Panayampalli S. Satheshkumar, Christina L. Hutson
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2023-12-01
Series:Emerging Infectious Diseases
Subjects:
mpox
viruses
antivirals
tecovirimat
ST-246
TPOXX
Online Access:https://wwwnc.cdc.gov/eid/article/29/12/23-1146_article

Similar Items

Similar Items